Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 11 » 1st World Lung Disease Summit

Diagnosis, assessment, and phenotyping of COPD: beyond FEV1

Authors Lange P, Halpin D, O’Donnell D, MacNee W, Finch D

Received 10 April 2015

Accepted for publication 6 July 2015

Published 18 February 2016 Volume 2016:11(1st World Lung Disease Summit) Pages 3—12

DOI https://doi.org/10.2147/COPD.S85976

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Richard Russell


Peter Lange,1,2 David M Halpin,3 Denis E O’Donnell,4 William MacNee5

1Respiratory Section, Hvidovre Hospital, Copenhagen, Denmark; 2Department of Health, University of Copenhagen, Copenhagen, Denmark; 3Royal Devon and Exeter Hospital, Exeter, UK; 4Respiratory Investigation Unit, Queen’s University and Kingston General Hospital, Kingston, ON, Canada; 5MRC Centre for Inflammation Research, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK


Abstract: COPD is now widely recognized as a complex heterogeneous syndrome, having both pulmonary and extrapulmonary features. In clinical practice, the diagnosis of COPD is based on the presence of chronic airflow limitation, as assessed by post-bronchodilator spirometry. The severity of the airflow limitation, as measured by percent predicted FEV1, provides important information to the physician to enable optimization of management. However, in order to accurately assess the complexity of COPD, there need to be other measures made beyond FEV1. At present, there is a lack of reliable and simple blood biomarkers to confirm and further assess the diagnosis of COPD. However, it is possible to identify patients who display different phenotypic characteristics of COPD that relate to clinically relevant outcomes. Currently, validated phenotypes of COPD include alpha-1 antitrypsin deficiency, and “frequent exacerbators”. Recently, a definition and assessment of a new phenotype comprising patients with overlapping features of asthma and COPD has been suggested and is known as “asthma COPD overlap syndrome”. Several other phenotypes have been proposed, but require validation against clinical outcomes. Defining phenotypes requires the assessment of multiple factors indicating disease severity, its impact, and its activity. Recognition and validation of COPD phenotypes has an important role to play in the selection of evidence-based targeted therapy in the future management of COPD, but regardless of the diagnostic terms, patients with COPD should be assessed and treated according to their individual treatable characteristics.

Keywords: COPD, asthma, ACOS, phenotype, diagnosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]